WebApr 13, 2024 · A phase II double-blind controlled trial in NASH of OCA in a dose of 25 mg daily for 72 weeks was performed in 283 NASH patients, 142 of whom received placebo … WebApr 23, 2015 · The Farnesoid X Receptor Ligand Obeticholic Acid in Nonalcoholic Steatohepatitis Treatment (FLINT) trial was sponsored by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). FLINT enrolled 283 adult NASH patients at eight U.S. centers comprising the NIDDK's NASH clinical research network (CRN).
National Center for Biotechnology Information
WebThe NASH FLINT data directory contains the following files, and the following raw datasets in Windows-based SAS, v.7-8-9 format: table1.sas7bdat – This analysis dataset contains … WebJan 9, 2014 · NEW YORK, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary … sigmoid part of large or small intestine
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver ...
WebObeticholic acid (OCA) was shown to improve fibrosis in patients with NASH in the FLINT trial; a post hoc analysis of these data was performed to determine the relationship … WebMethods: In the Phase 2b FLINT trial, patients were randomised (1:1) to receive 25 mg OCA or placebo once daily for 72 weeks. Aspartate aminotransferase:platelet ratio index (APRI), fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease fibrosis score (NFS) were evaluated in serum at baseline and weeks 24, 48, 72 and 96. WebNASH Treatment (FLINT) trial was a multicentre, randomised trial of 72 weeks of obeticholic acid versus placebo in patients with biopsy evidence of non-alcoholic … the prism and the rainbow